Mesoblast MEOBF
NASDAQ MEOBF
$1.90 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

Mesoblast (MEOBF) Total Non-Current Liabilities (2015 - 2026)

Mesoblast's (MEOBF) quarterly Total Non-Current Liabilities came in at $123.6 million in Q2 2026, up 46.03% year-over-year from $84.6 million in Q2 2025, and up 55.32% quarter-over-quarter from $79.6 million in Q4 2025.

Analysis

Mesoblast (MEOBF) Total Non-Current Liabilities (2015 - 2026) Analysis & Trends

Mesoblast has disclosed Total Non-Current Liabilities across 12 years of filings, most recently posting $123.6 million for Q2 2026.

  • In Q2 2026, Total Non-Current Liabilities rose 46.03% year-over-year to $123.6 million; the TTM figure through Jun 2026 stood at $123.6 million (up 46.03% YoY), while the FY2026 annual figure was $123.6 million, up 46.03% from the prior year.
  • Total Non-Current Liabilities came in at $123.6 million for Q2 2026 at Mesoblast, up from $79.6 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $123.6 million in Q2 2026 to a low of $8.2 million in Q1 2023.
  • Average Total Non-Current Liabilities over 5 years is $41.7 million, with a median of $14.9 million recorded in 2022.
  • Year-over-year, Total Non-Current Liabilities slumped 91.89% in 2022 and soared 651.86% in 2025.
  • Over 5 years, Total Non-Current Liabilities stood at $9.0 million in 2022, then jumped by 89.74% to $17.1 million in 2023, then plunged by 38.02% to $10.6 million in 2024, then soared by 651.86% to $79.6 million in 2025, then soared by 55.32% to $123.6 million in 2026.
  • Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $123.6 million in Q2 2026, $79.6 million in Q4 2025, and $84.6 million in Q2 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Krystal Biotech 10.27 Bn 9.43 Bn 112.79 Mn 134.44 Mn
2 CRISPR Therapeutics AG 5.17 Bn 5.17 Bn - 898.00 Mn
3 Iovance Biotherapeutics 3.79 Bn 3.49 Bn 55.72 Mn 72.64 Mn
4 Legend Biotech 3.68 Bn 2.71 Bn 251.50 Mn 117.70 Mn
5 uniQure 3.05 Bn 3.05 Bn 5.49 Mn 577.71 Mn
6 Beam Therapeutics 2.65 Bn 2.65 Bn - 313.33 Mn
7 Precigen 2.44 Bn 2.44 Bn 52.17 Mn 126.64 Mn
8 Sarepta Therapeutics 2.33 Bn 1.53 Bn 251.87 Mn 1.66 Bn
9 Vericel 1.99 Bn 1.83 Bn 56.40 Mn 130.91 Mn
10 Mesoblast 246.02 Mn 143.11 Mn - 123.56 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 123.56 Mn
Dec 31, 2025 79.55 Mn
Jun 30, 2025 84.62 Mn
Dec 31, 2024 10.58 Mn
Jun 30, 2024 115.56 Mn
Dec 31, 2023 17.07 Mn
Jun 30, 2023 16.61 Mn
Mar 31, 2023 8.17 Mn
Dec 31, 2022 9.00 Mn
Sep 30, 2022 9.85 Mn
Jun 30, 2022 12.52 Mn
Mar 31, 2022 13.18 Mn
Dec 31, 2021 110.98 Mn
Sep 30, 2021 69.17 Mn
Jun 30, 2021 17.02 Mn
Mar 31, 2021 17.82 Mn
Dec 31, 2020 19.44 Mn
Sep 30, 2020 20.72 Mn
Jun 30, 2020 27.56 Mn
Mar 31, 2020 28.11 Mn